Researchers at Sidra Medicine, a member of Qatar Foundation, have published the Middle East’s first population-scale atlas showing how genetic variation regulates gene activity in blood. The work appeared in Nature Genetics under the title “A catalogue of transcriptome genetic regulation in a consanguineous Middle Eastern biobank.” It identifies nearly 30,000 causal regulatory effects and ties them to 20 clinical traits and disease pathways, including immune and metabolic function.

The team was led by Prof. Younes Mokrab, with Dr. Haroon Naeem as first author. They used data from nearly 2,000 Qatar Biobank participants.

How does it work?

The idea is simple to state. The genome is the blueprint, and the blood transcriptome shows which parts of that blueprint are being used. The team combined whole-genome sequencing, whole-blood transcriptomics and detailed clinical records for each participant.

They then went beyond ordinary association studies. Advanced computational methods let them separate variants that merely sit near a gene from those that cause changes in how it is transcribed. That distinction matters, because association alone rarely tells a clinician or a drug developer what to act on.

The study also looked at consanguinity, which is common in the region. Inheriting two copies of the same variant is best known as a driver of rare recessive diseases. The researchers showed it can also push specific genes to unusually high or low activity when the variants involved are regulatory. So the biological reach of consanguinity is wider than protein-altering mutations alone.

Why does it matter?

The practical gains are concrete. Better annotation of non-coding variants should raise the yield of genetic diagnosis, which is a persistent frustration when test results come back unclear. The data also support ancestry-aware polygenic scores, which estimate risk for complex diseases more accurately than scores built mainly on European cohorts.

There is a drug development angle too. Linking variants to their target genes helps prioritize biomarkers and therapeutic targets that are grounded in disease biology, which can improve the odds of clinical trial success.

Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, put it plainly: precision medicine depends on population-matched reference databases. This study adds an RNA layer to the DNA resources Qatar has built over the years.

The context

Global genomics has long drawn its reference data from a narrow slice of humanity. Arab and Middle Eastern genomes remain thin in those databases, which means tools trained elsewhere can misjudge risk here. National programs across the GCC, from Qatar’s genome efforts to Saudi Arabia’s work under Vision 2030 and the UAE’s genomics initiatives, are trying to correct that imbalance. Qatar’s contribution is notable for pairing the data with a population where consanguinity is high.

The study drew on Qatar Biobank and the Qatar Genome Program, now part of the Qatar Precision Health Institute, with support from Sidra Medicine and the Qatar National Research Fund. The dataset is being enriched with more omics layers from the biobank and from disease cohorts at Sidra. The stated aim is to feed AI and machine learning models for disease prediction and treatment discovery.

That ambition is realistic only if the underlying data are good, and regionally representative data are exactly what has been missing. For health ministries and investors weighing genomic medicine, the message is that the reference infrastructure is starting to exist. The full paper is available in Nature Genetics.

The post Qatar builds the Middle East’s first atlas of DNA variants that control gene activity appeared first on DH Arab.

The hospital has become the first in the Middle East and North Africa to offer a food intolerance test that uses endomicroscopy. The technique lets doctors see how cells in the small intestine respond to specific foods in real time. The service has been approved by the Department of Health, Abu Dhabi, which matters in a market where new clinical procedures face close regulatory scrutiny.

How does it work?

The test builds on a standard endoscopy. A specialist passes a flexible scope into the upper digestive tract, and a tiny microscope probe is used to magnify the lining of the small intestine to the cellular level. The patient is then exposed to suspected trigger foods, and the doctor watches the tissue for signs of reaction, such as gaps opening between cells or fluid leaking into the gut wall.

That is a different approach from the blood tests and elimination diets most clinics rely on. Those methods measure indirect signals or depend on a patient’s own memory of symptoms. Endomicroscopy observes the tissue itself. The result is a visible, patient-specific answer rather than a statistical hint.

Why does it matter?

Digestive complaints are common across the Gulf, and so is frustration with diagnosis. Patients often move between clinics for months, trying one diet after another. A test that links a named food to a visible cellular response could shorten that journey and spare people from needlessly restrictive eating.

There is a caution, though. The procedure is invasive compared with a blood draw, and it requires specialist equipment and training. It will suit patients with persistent, unexplained symptoms rather than anyone with mild bloating after a heavy meal. Clinicians will need to be clear about who should be referred.

The context

The launch fits a wider pattern in the UAE. Abu Dhabi has spent years positioning itself as a centre for advanced, personalised medicine, with genomics programmes, AI-assisted diagnostics and international hospital partnerships all part of that effort. Saudi Arabia’s Vision 2030 health goals point in the same direction: bring complex, specialised care closer to home and reduce the number of patients travelling abroad for it.

Offering a regional first also strengthens the case for medical tourism. Patients from neighbouring GCC states and beyond may now find a diagnostic option in Abu Dhabi that previously meant a trip to Europe or North America.

The real test will be evidence. Hospitals, insurers and regulators will want outcome data showing that patients who follow the results actually feel better. If that data arrives, endomicroscopy could become a standard tool for stubborn digestive cases. If not, it remains an impressive image. For now, Abu Dhabi has the technology, and the region will be watching what it shows.

The post Cleveland Clinic Abu Dhabi lets doctors watch the gut react to food appeared first on DH Arab.

The Memorandum of Understanding sets a framework for cooperation across four areas: specialised clinical services, physician expertise, medical innovation and professional development. It is a framework, not a finished programme. The detailed terms, timelines and financial arrangements have not been made public, so the real test lies in what the two organisations build on it.

How will it work?

The MoU is built around the four areas of cooperation, and each one points to a practical benefit.

• Specialised clinical services: patients at either site may gain easier access to services the other provider is better equipped to deliver.
• Physician expertise: doctors can share knowledge and experience across both organisations.
• Medical innovation: the partners can explore new approaches to care together.
• Professional development: training and learning opportunities can be offered to clinical teams on both sides.

In practice, this kind of agreement usually starts with referral pathways and joint training sessions, then grows if the early results are good. That is a reasonable expectation here, though neither party has confirmed a rollout schedule.

Why does it matter?

For patients, the gain is continuity. A clinic in a residential community such as Khalifa City can be the first point of contact, while a hospital provides deeper specialist capacity. When the two work under a formal arrangement, the handover between them should be smoother and faster.

For clinicians, the value is in the exchange. Smaller facilities often struggle to keep teams current across every specialty. Shared development programmes help close that gap without every provider building everything alone.

And for the sector, it is a signal. Private providers in Abu Dhabi are choosing collaboration over going it alone, which is what policymakers have been encouraging for years.

The context

The setting matters. The Future Health Summit is one of several forums in the UAE where providers, regulators and investors line up announcements around the national health agenda. Abu Dhabi has pushed hard to raise care standards, widen specialist access and bring innovation into everyday practice, and the Department of Health has made integrated care a clear priority.

The same thinking runs across the GCC. Saudi Arabia’s Vision 2030 health transformation programme rests on connected, patient-centred care, and other member states are moving in a similar direction. Partnerships like this one are how that policy reaches the ground, one agreement and one referral at a time.

Still, an MoU is an intention, not an outcome. The measure of success will be simple: shorter waits, better coordination and trained staff who stay. If Reem Hospital and Yas Clinic Khalifa City can show that, others in the emirate will likely follow.

The post Reem Hospital and Yas Clinic Khalifa City join forces in Abu Dhabi appeared first on DH Arab.

The treatment under study is MB-111, an investigational therapy for patients with severely elevated blood lipid levels. The source announcement was brief, so some trial details, including enrolment numbers, timelines and the exact target gene, have not yet been made public. What is clear is the milestone itself: the country’s first trial of this kind.

How will it work?

LNPs are tiny fat-based capsules that carry genetic instructions into cells. Many people know them from mRNA COVID-19 vaccines. Here, the same delivery method is used to carry gene-editing tools to the liver, where cholesterol and other blood fats are regulated.

The idea is simple to state and hard to execute. Instead of asking patients to take daily pills or regular injections for life, a gene-editing therapy aims to change how the body handles lipids at the source. In principle, one treatment could produce a lasting effect. Whether MB-111 does so is exactly what a clinical trial must establish.

IROS will manage the study locally. That means recruiting eligible patients, coordinating sites, and handling regulatory and data requirements. Mammoth Biosciences brings the therapy and the editing technology behind it.

Why does it matter?

Severely raised blood lipids are a serious problem in the Gulf. Cardiovascular disease is a leading cause of death across the GCC, and high rates of diabetes and obesity add to the risk. Patients with inherited or treatment-resistant lipid disorders often cannot reach safe levels with standard drugs alone.

But the significance goes beyond one drug. Running an early gene-editing trial inside the UAE means local clinicians gain direct experience with the therapy, and local patients get access to research that would otherwise happen abroad. It also tests whether regulators, hospitals and laboratories can handle the safety monitoring these studies demand.

That capability is hard to build and easy to lose. A first trial creates a template for the second and third.

The context

M42 was created to turn Abu Dhabi into a hub for genomics, precision medicine and clinical research. The Emirati Genome Programme, which has sequenced hundreds of thousands of people, gives that ambition a data foundation. A gene-editing trial is the logical next step: a place where genomic knowledge meets treatment.

The move also fits wider regional strategy. Saudi Arabia’s Vision 2030 prioritises life sciences and local clinical research, and the UAE has spent years courting global biotech firms with faster approvals and strong hospital networks. Partnerships like this one are how those policies become real studies with real patients.

Challenges remain. Gene-editing therapies are expensive, long-term safety data is still limited, and early-phase results can disappoint. Still, the Gulf is no longer waiting for these treatments to arrive. It is helping test them. For healthcare leaders in the region, that shift deserves close attention.

The post The UAE is about to run its first gene-editing trial for a cholesterol disorder appeared first on DH Arab.

The two companies have signed a partnership to explore sustainability, digital innovation and operational improvements across PureHealth’s facilities and infrastructure. The announcement is an agreement to explore, not a finished programme. Still, the direction is clear, and it matters for anyone running a health system in the Gulf.

How will it work?

Schneider Electric will give PureHealth access to its EcoStruxure Resource Advisor platform, a tool that gathers energy, water and emissions data in one place. The source material is cut off after that point, so further details of the rollout are not yet public. But the logic of such a tool is well established.

Facilities teams typically hold data in separate systems, from chillers and lighting to power supply and water use. Bringing it together lets managers spot waste, compare sites and report progress against targets. The wider collaboration will look at digital tools and infrastructure upgrades across PureHealth’s hospitals and clinics.

Expect the early work to focus on measurement. You can’t cut what you can’t see, and many healthcare groups still lack a clear, consolidated picture of their own consumption.

Why does it matter?

Healthcare is a heavy emitter. Operating theatres, imaging suites, laboratories and strict air quality requirements all demand constant power and cooling, and in the Gulf climate the cooling load alone is substantial. Every dirham saved on utilities is a dirham that can go back into patient care.

There is also a reputational and regulatory angle. Hospital operators across the region are being asked to show progress on net zero, and the UAE has set a 2050 target. A group the size of PureHealth, with a large portfolio of hospitals, clinics and diagnostics, can move the national numbers on its own.

And the digital side is not a side issue. Operational data helps leaders plan maintenance, reduce downtime and keep critical equipment running. In a hospital, that is a clinical safety matter as much as a financial one.

The context

PureHealth was created to consolidate Abu Dhabi’s public and private healthcare assets under one umbrella, and it has grown quickly through acquisitions and partnerships. Scale brings a difficult side effect: dozens of buildings with different ages, systems and standards. Standardising how they are monitored is a practical first step.

The deal also fits a wider GCC pattern. Saudi Arabia’s Vision 2030 pushes hospitals toward efficiency and private sector participation, while the UAE is tying health strategy to its Net Zero 2050 commitment and national digital agenda. Governments want healthcare that is both higher quality and cheaper to run.

So the real test is delivery. Partnerships to explore are common in this region. Those that publish baselines, set targets and report results are rarer, and they are the ones that will change how Gulf hospitals are built and operated.

The post Schneider Electric and PureHealth bet that greener hospitals will also run better appeared first on DH Arab.

The Ministry of Interior’s Medical Services, through Security Forces Hospital in Riyadh, has carried out the first robot-assisted breast reconstruction in Saudi Arabia. The patient is a 43-year-old woman who had already undergone a nipple- and skin-sparing mastectomy after a breast cancer diagnosis. The hospital reports that the operation was successful.

How did it work?

The technique belongs to the family of procedures that rebuild the breast with the patient’s own tissue. Surgeons took skin and fat from the abdomen and moved it to the chest using microsurgery, which means joining tiny blood vessels under magnification so the transferred tissue stays alive.

Done conventionally, this is demanding work. It calls for a specialized team and careful planning. The difference here is in how the tissue was harvested. The robotic system let the team work through very small incisions and preserve the integrity of the abdominal wall.

That matters because the abdominal wall is where conventional harvesting tends to cause trouble. Larger incisions raise the risk of hernias and abdominal bulging. A minimally invasive approach cuts that risk, and the hospital says it also improves surgical precision.

Why does it matter?

Reconstruction is not cosmetic polish. For women who have lost a breast to cancer, it affects quality of life, psychological well-being and self-confidence. Those outcomes shape how well a patient recovers, not just how she feels about the result.

So any method that reduces the physical price of reconstruction is worth attention. A patient who avoids a weakened abdominal wall has one fewer long-term problem to manage. That is the practical promise of this approach, though the hospital has so far reported a single case, and larger series will be needed to show how consistently the benefit holds.

The context

Breast cancer is a major concern across the GCC, and it is often diagnosed in younger women than in many Western countries. Surgical care that goes beyond removing the tumor is becoming a more visible part of cancer services in the region.

This operation also fits the direction set by Saudi Vision 2030 and the Health Sector Transformation Program, which push for higher-quality specialized care and wider adoption of advanced technology inside the Kingdom. Robotic surgery is already established in urology and general surgery in the Gulf. Moving it into microsurgical reconstruction is a more delicate test of skill and training.

The Ministry of Interior’s Medical Services describes the case as part of its wider effort to adopt the latest surgical innovations and raise the quality of care for beneficiaries. The next questions are practical ones. How many patients will be eligible, how many surgeons will be trained, and whether other major centers in Saudi Arabia and the wider Gulf will follow. If the early result holds, regional breast cancer programs will have a strong reason to invest in the same capability.

The post Saudi surgeons rebuild a breast through tiny incisions, and spare the abdominal wall appeared first on DH Arab.

Imperial College London Diabetes & Endocrine Centre (ICLDEC), part of M42, and Rochester Institute of Technology Dubai (RIT Dubai) have signed a Memorandum of Understanding (MoU). The goal is to equip healthcare professionals with the data and technology skills that clinical practice and research now require.

How will it work?

The MoU is a framework, not yet a finished curriculum, so details will emerge as the two institutions begin working together. The logic is clear, though. ICLDEC brings clinical and research depth in diabetes and endocrinology, along with access to the patient realities that M42’s network sees every day. RIT Dubai brings technical teaching strength in computing, data science and applied technology.

Together, they are expected to build training that links the two worlds. That could include:

• Short courses in data analysis and digital tools for working clinicians
• Joint research projects that pair medical and technical expertise
• Academic exchange between teams at both institutions

The practical aim is simple. A clinician should leave with skills they can use on Monday morning, not just theory.

Why does it matter?

Diabetes is the obvious test case. The UAE has one of the higher diabetes burdens in the world, and the condition generates enormous amounts of data, from glucose monitors to genomic records. That information only helps patients if clinicians can interpret it with confidence.

But there is a wider issue. Hospitals across the Gulf are buying artificial intelligence tools, building digital records and launching remote monitoring programs. Technology is arriving faster than the workforce is being prepared to use it. And a tool in the hands of an untrained user is a risk, not an asset.

So the real value here is human capital. Investing in people who can work at the point where medicine and technology meet is arguably a better bet than another software purchase.

The context

This fits a clear regional pattern. Abu Dhabi has made genomics, precision medicine and digital health central to its health strategy, and M42 is one of the main vehicles for that ambition. Dubai, meanwhile, has pushed hard on digital health records and smart services, and RIT Dubai sits within that technology-minded academic scene.

Across the GCC, national plans including Saudi Vision 2030 share the same priorities: preventive care, digital transformation and a skilled local workforce. Each depends on clinicians who are comfortable with data. Policy documents can set the direction, but training programs decide whether anyone arrives.

Still, an MoU is a starting point. The test will come in the months ahead: how many professionals are trained, how quickly programs launch and whether the skills change daily practice. If the partnership delivers, it could become a template for other health systems in the region. If it stays on paper, it will be one more agreement among many.

The post Doctors are learning to code, and Abu Dhabi wants to lead the lesson appeared first on DH Arab.

The deal is subject to customary closing conditions and clearance from Morocco’s Competition Council. ABA Life, founded in 2021, is the healthcare arm of ABA Technology, which was founded and is chaired by Mohamed Benouda. It combines artificial intelligence, medical technology, telemedicine, connected health infrastructure and clinical services. It also works with public institutions and foundations on programmes meant to widen access to care.

The funds will be used for…

The money is split across three priorities:

• Expanding the “AI for Sovereign Health” programme, including the Mediot AI platform and clinical intelligence tools
• Deploying the group’s healthcare technologies and services at larger scale
• Entering international markets

Benouda says the aim is to make ABA Life a global healthtech reference and one of Morocco’s next unicorns. Admaius’ Selim Ettriqui pointed to the company’s mix of medical devices, connected infrastructure, care operations and proprietary technology built in Morocco.

Why does it matter?

Profitability and public-sector partnerships are a strong combination. Many health AI ventures depend on pilots that never grow. ABA Life argues it has already moved past that stage, and an investor with a pan-African mandate appears to agree. Marlon Chigwende, Managing Partner at Admaius, cited a proven business model and strong technology foundations.

The word “sovereign” also matters. It signals that clinical AI can be developed and controlled locally rather than imported. That idea will be familiar to Gulf readers.

The context

Across the GCC, governments are building national health data platforms and AI strategies under programmes such as Saudi Vision 2030 and the UAE’s digital health initiatives. Data governance and local capability sit at the centre of those plans. Morocco is chasing a similar goal from a different starting point.

So the questions for ABA Life are practical. Can a model built around Moroccan public partnerships travel? Will regulators in other markets accept its clinical AI? And can it keep its margins while expanding? Gulf health authorities and investors looking for partners in North and West Africa will be watching the answers.

The post ABA Life lands $40 million to build a Moroccan healthtech champion appeared first on DH Arab.

The study is called CARE-UAE. It ran at Cleveland Clinic Abu Dhabi and enrolled 25 patients between October 15 and 23, 2026. All were already scheduled for screening, diagnostic or surveillance colonoscopy. The work is a partnership with US firm Neptune Medical and has the backing of the Department of Health, Abu Dhabi (DoH). It was highlighted at the Abu Dhabi Future Health Summit 2026. Organisers describe it as one of the first studies of its kind in the emirate, and it is the first clinical evaluation of Neptune’s Triton Robotic Endoscopy System in the Middle East.

Twenty-five patients is a small number. Nobody should read results into it yet. But the point of an early study like this is to test whether the technology behaves well in a new clinical setting, and to start building local evidence.

How did it work?

CARE-UAE has two parts, and they are separate.

The first part assesses the Triton system’s navigation and shape-tracking features. These are designed to help clinicians guide the endoscope through the colon. A key test is whether the device reaches the caecum, the start of the large intestine. Reaching it is the standard anatomical marker that an examination is complete.

The second part collects data using an AI-assisted polyp detection platform. This platform is not part of Triton. Neptune plans to fold similar capabilities into future versions of the system, so the data will inform that work.

Dr. John Rodriguez, Chief of the Digestive Disease Institute at Cleveland Clinic Abu Dhabi, said the technology should help clinicians recognise and remove polyps that standard colonoscopy can easily miss. That is a hope for now, not a finding.

Why does it matter?

Early detection is the whole game in colorectal cancer. Precancerous polyps can be removed before they turn dangerous, so a missed polyp is a missed chance. Any tool that improves detection or makes the procedure more reliable could change outcomes at scale.

Neptune CEO Alex Tilson pointed to the company’s earlier CARE 1 and CARE 2 studies and its recent FDA clearance as milestones. He said real-world data on AI-assisted detection is central to the next generation of Triton.

The regulatory message is just as important. Dr. Asma Ibrahim Al Mannaei of the DoH said emerging technologies must be evaluated rigorously, with patient safety at the centre. Abu Dhabi wants to contribute to international research while building evidence in its own clinical setting.

The context

This fits a clear pattern across the Gulf. The UAE has positioned itself as a leader in AI, and Abu Dhabi has made health research and life sciences a policy priority. The summit’s theme, ‘To Sense Is to Predict’, reflects the same logic: earlier insight, earlier action. Its four impact areas included Digital Health and AI and Investment in Life Sciences. The wider GCC, under national strategies such as Saudi Vision 2030, is pursuing similar goals in digital health and preventive care.

Dr. Georges-Pascal Haber, CEO of Cleveland Clinic Abu Dhabi, said the ambition is to create solutions in Abu Dhabi that set standards of care globally. That is a big claim for a 25-patient study. Still, hosting early clinical evaluations is how a health system earns a seat in medtech development, rather than simply buying the result later.

The real test will come with larger studies and hard data on detection rates. For now, CARE-UAE shows that Abu Dhabi has the regulatory framework, clinical expertise and appetite to run such trials. Its findings will add to the evidence on robotic endoscopy and guide further development.

The post A robot, an AI and 25 patients: Abu Dhabi tests the next colonoscopy appeared first on DH Arab.

The initial programmes cover four areas: neuroscience, cardiovascular disease, oncology and immunology. These are not niche choices. Heart disease, cancer and neurological conditions weigh heavily on health systems across the GCC, and immunology is a growing concern as autoimmune and inflammatory conditions are diagnosed more often.

How does it work?

The hub links Novartis’s global Phase 3 research with Abu Dhabi’s hospitals, clinicians and regulatory system. Instead of treating the emirate as a late stop for approved drugs, the model brings patients into studies while those studies are still running. The same protocols apply as anywhere else in the world, which is what makes the data usable for international approval.

The DoH acts as both regulator and convener. That matters. Trial delays often come from slow approvals, fragmented ethics review and difficulty recruiting patients. A single authority that sets the rules and backs the programme can shorten each of those steps. Whether it does so in practice is the thing to watch.

Why does it matter?

For patients, the benefit is direct. Participants may gain early access to therapies years before they are widely available, along with close monitoring by specialist teams. For clinicians, running global trials builds skills and credibility that stay in the system long after a study closes.

There is an economic argument too. Clinical research brings investment, skilled jobs and links with international pharmaceutical companies. And there is a scientific one. Gulf populations are underrepresented in trial data, so treatments are often tested on people whose genetics, diets and disease patterns differ from those of the region. Local participation helps fix that.

The context

The hub fits neatly into Abu Dhabi’s long-running effort to build a life sciences sector, and into the wider UAE strategy of moving from importing healthcare to producing knowledge. Saudi Arabia’s Vision 2030 sets similar goals, with research capacity and local health industries high on the agenda. Across the GCC, governments are competing, and cooperating, to become credible research destinations.

But credibility has to be earned. Trial sponsors look for fast enrolment, clean data and reliable regulators. Abu Dhabi has the funding and the infrastructure. It now needs volume, and a steady record of delivery.

If the Novartis programmes meet those tests, other companies are likely to follow. That would turn a single partnership into a real regional research base, and give Gulf patients a place in the evidence that shapes their own treatment.

The post Abu Dhabi wants to be where the world’s drug trials happen appeared first on DH Arab.